Finch Therapeutics Group, Inc.
FNCH · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.01 | -0.02 | 0.01 |
| FCF Yield | -218.01% | -106.53% | -63.69% | -63.28% |
| EV / EBITDA | -2.49 | -2.52 | -2.33 | -2.80 |
| Quality | ||||
| ROIC | -13.49% | -10.20% | -6.65% | -6.46% |
| Gross Margin | 0.00% | 0.00% | -1.55% | 0.00% |
| Cash Conversion Ratio | 0.98 | 1.13 | 1.22 | 2.18 |
| Growth | ||||
| Revenue 3-Year CAGR | -39.53% | -42.96% | -45.79% | -81.94% |
| Free Cash Flow Growth | -8.34% | -18.15% | 29.82% | 42.55% |
| Safety | ||||
| Net Debt / EBITDA | -2.14 | -1.72 | -1.08 | -0.54 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -59.32 | -98.37 | -288.41 | -617.88 |